loading
4 D Molecular Therapeutics Inc stock is traded at $5.665, with a volume of 325.91K. It is down -1.22% in the last 24 hours and up +43.29% over the past month. 4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
See More
Previous Close:
$5.73
Open:
$5.53
24h Volume:
325.91K
Relative Volume:
0.34
Market Cap:
$261.83M
Revenue:
$20.72M
Net Income/Loss:
$-100.84M
P/E Ratio:
-2.1297
EPS:
-2.66
Net Cash Flow:
$-78.56M
1W Performance:
+25.78%
1M Performance:
+43.29%
6M Performance:
-5.19%
1Y Performance:
-61.52%
1-Day Range:
Value
$5.4204
$5.69
1-Week Range:
Value
$4.99
$6.69
52-Week Range:
Value
$2.235
$17.41

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Name
Name
4 D Molecular Therapeutics Inc
Name
Phone
(510) 505-2680
Name
Address
5858 HORTON STREET #455, EMERYVILLE
Name
Employee
227
Name
Twitter
Name
Next Earnings Date
2024-12-13
Name
Latest SEC Filings
Name
FDMT's Discussions on Twitter

Compare FDMT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
FDMT
4 D Molecular Therapeutics Inc
5.6521 280.26M 20.72M -100.84M -78.56M -2.66
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
383.34 96.11B 11.42B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.49 60.40B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
429.20 54.91B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
671.01 41.30B 3.05B 1.28B -614.78M 19.58
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.05 33.25B 3.81B -644.79M -669.77M -6.24

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-13-25 Downgrade BMO Capital Markets Outperform → Market Perform
Nov-21-24 Initiated Morgan Stanley Underweight
Sep-23-24 Downgrade Cantor Fitzgerald Overweight → Neutral
Apr-15-24 Initiated Barclays Overweight
Feb-07-24 Resumed Goldman Buy
Oct-26-23 Initiated RBC Capital Mkts Outperform
Oct-24-23 Initiated Cantor Fitzgerald Overweight
Oct-18-23 Upgrade Leerink Partners Market Perform → Outperform
Jul-05-23 Initiated Chardan Capital Markets Buy
Jan-30-23 Initiated BMO Capital Markets Outperform
Nov-18-22 Initiated H.C. Wainwright Buy
Nov-15-22 Upgrade Goldman Neutral → Buy
Aug-12-22 Downgrade SVB Leerink Outperform → Mkt Perform
Jun-22-22 Initiated Jefferies Buy
Jan-04-22 Initiated SVB Leerink Outperform
Jan-05-21 Initiated BofA Securities Buy
Jan-05-21 Initiated Evercore ISI Outperform
Jan-05-21 Initiated Goldman Neutral
View All

4 D Molecular Therapeutics Inc Stock (FDMT) Latest News

pulisher
04:01 AM

Published on: 2025-08-07 03:01:11 - Newser

04:01 AM
pulisher
02:49 AM

4D Molecular Therapeutics (FDMT) to Release Earnings on Thursday - Defense World

02:49 AM
pulisher
Aug 06, 2025

4D Molecular Therapeutics shares fall 2.73% intraday after announcing participation in H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. - AInvest

Aug 06, 2025
pulisher
Aug 06, 2025

Volatility clustering patterns for 4D Molecular Therapeutics Inc.Short-Term Sector Movement Forecast Generator - Newser

Aug 06, 2025
pulisher
Aug 05, 2025

Using fundamentals and technicals on 4D Molecular Therapeutics Inc.AI Volatility Forecast and Risk Monitor - Newser

Aug 05, 2025
pulisher
Aug 04, 2025

How to build a custom watchlist for 4D Molecular Therapeutics Inc.Entry Opportunity Screener with Confirmation - Newser

Aug 04, 2025
pulisher
Aug 04, 2025

Fibonacci Support Holding Strong in 4D Molecular Therapeutics Inc.Conservative Long Term Growth Plans Under Review - beatles.ru

Aug 04, 2025
pulisher
Aug 04, 2025

Why is 4D Molecular Therapeutics Inc. stock attracting strong analyst attentionAchieve consistent profits with proven methods - Jammu Links News

Aug 04, 2025
pulisher
Aug 04, 2025

4D Molecular Therapeutics’ (FDMT) Buy Rating Reiterated at Chardan Capital - Defense World

Aug 04, 2025
pulisher
Aug 03, 2025

Is 4D Molecular Therapeutics Inc. a growth stock or a value stockProven strategies for superior portfolio growth - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What is the dividend policy of 4D Molecular Therapeutics Inc. stockGet daily expert analysis on top stocks - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Is 4D Molecular Therapeutics Inc. Stock a Good Fit for Conservative InvestorsFree Capital Preserving Trade Plan Templates - Newser

Aug 03, 2025
pulisher
Aug 03, 2025

What is the risk reward ratio of investing in 4D Molecular Therapeutics Inc. stockExplosive capital gains - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are 4D Molecular Therapeutics Inc. company’s key revenue driversCapitalize on fast-growing investment opportunities - Jammu Links News

Aug 03, 2025
pulisher
Aug 02, 2025

Does 4D Molecular Therapeutics Inc. stock perform well during market downturnsRapid profit acceleration - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

Is 4D Molecular Therapeutics Inc. stock overvalued or undervaluedInvest smarter with data-backed trading alerts - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

What are the technical indicators suggesting about 4D Molecular Therapeutics Inc.Spectacular growth rates - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

When is 4D Molecular Therapeutics Inc. stock expected to show significant growthMassive stock growth - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

Why 4D Molecular Therapeutics Inc. stock attracts strong analyst attentionFree Low Risk Swing Trade Opportunity List - Newser

Aug 02, 2025
pulisher
Aug 01, 2025

4D Molecular Therapeutics Inc. stock prediction for this weekLow Drawdown Picks with Weekly Updates - Newser

Aug 01, 2025
pulisher
Aug 01, 2025

4D Molecular Therapeutics Showcases Positive Trial Results, Charts New Growth Trajectory - timothysykes.com

Aug 01, 2025
pulisher
Aug 01, 2025

4D Molecular (FDMT) Stock Climbs Following Promising Retina Therapy Data - Stocks Telegraph

Aug 01, 2025
pulisher
Aug 01, 2025

4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study - 富途牛牛

Aug 01, 2025
pulisher
Aug 01, 2025

How volatile is 4D Molecular Therapeutics Inc. stock compared to the marketEntry Signal Forecasts With Low Risk - Jammu Links News

Aug 01, 2025
pulisher
Aug 01, 2025

4D Molecular: Time to Buy After Recent Surge? - StocksToTrade

Aug 01, 2025
pulisher
Aug 01, 2025

4D Molecular Therapeutics: A Market Shift? - timothysykes.com

Aug 01, 2025
pulisher
Aug 01, 2025

4D Molecular Therapeutics shares rise 30.44% premarket after presenting positive 60-week results for 4D-150. - AInvest

Aug 01, 2025
pulisher
Aug 01, 2025

Chardan Capital Maintains Buy on 4D Molecular, Raises PT to $25 - AInvest

Aug 01, 2025
pulisher
Aug 01, 2025

4D Molecular Therapeutics stock soars after positive DME trial results By Investing.com - Investing.com Canada

Aug 01, 2025
pulisher
Aug 01, 2025

Will a bounce in 4D Molecular Therapeutics Inc. offer an exitPrice Action Trading with Volume Confirmation - Newser

Aug 01, 2025
pulisher
Aug 01, 2025

4D Molecular Therapeutics Shares Surge 50.89% on Positive Clinical Trial Results - AInvest

Aug 01, 2025
pulisher
Aug 01, 2025

4D Molecular Therapeutics (FDMT) Shares Soar 37.78% on Positive Clinical Trial Results - AInvest

Aug 01, 2025
pulisher
Aug 01, 2025

4D Molecular Therapeutics shares rise 56% premarket after presenting positive 60-week results for 4D-150. - AInvest

Aug 01, 2025
pulisher
Jul 31, 2025

4D Molecular (FDMT) Shows Promising Results in Clinical Trial fo - GuruFocus

Jul 31, 2025
pulisher
Jul 31, 2025

4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update - GlobeNewswire

Jul 31, 2025
pulisher
Jul 31, 2025

Breakthrough: 4D-150 DME Treatment Shows 78% Reduction in Injections, FDA and EMA Clear Path to Approval - Stock Titan

Jul 31, 2025
pulisher
Jul 31, 2025

How does 4D Molecular Therapeutics Inc. compare to its industry peersBeginner Investor Strategy With Proven Results - Jammu Links News

Jul 31, 2025
pulisher
Jul 30, 2025

What makes 4D Molecular Therapeutics Inc. stock attractive to long term investorsOversold Reversal Picks with Buy Zone - Newser

Jul 30, 2025
pulisher
Jul 30, 2025

Trend Reversal Possible in 4D Molecular Therapeutics Inc. Charts IndicateEarnings Play Trade Plan With Alerts Shared - beatles.ru

Jul 30, 2025
pulisher
Jul 30, 2025

Advanced analytics toolkit walkthrough for 4D Molecular Therapeutics Inc.Real Time Trade Execution Alert Plan - Newser

Jul 30, 2025
pulisher
Jul 30, 2025

Weiss Ratings Reiterates Sell (D-) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World

Jul 30, 2025
pulisher
Jul 29, 2025

Published on: 2025-07-29 16:44:26 - Newser

Jul 29, 2025
pulisher
Jul 29, 2025

How 4D Molecular Therapeutics Inc. stock performs during market volatilityPortfolio Positioning Strategy With Timing - Newser

Jul 29, 2025
pulisher
Jul 29, 2025

What makes 4D Molecular Therapeutics Inc. stock price move sharplyMinimal Risk Growth Investment Opportunity Analysis - Newser

Jul 29, 2025
pulisher
Jul 29, 2025

4D Molecular Therapeutics Bets Big On Gene Therapy Breakthroughs - Finimize

Jul 29, 2025
pulisher
Jul 29, 2025

Published on: 2025-07-29 09:03:48 - metal.it

Jul 29, 2025
pulisher
Jul 28, 2025

Published on: 2025-07-29 02:38:48 - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

Trapped Investors in 4D Molecular Therapeutics Inc. Await Breakout SignalTriple Digit Return Stock Predictions Released - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

What catalysts could drive 4D Molecular Therapeutics Inc. stock higher in 2025Stay informed with expert market forecasts - Jammu Links News

Jul 28, 2025
pulisher
Jul 28, 2025

How does 4D Molecular Therapeutics Inc. generate profit in a changing economyUnlock powerful market trend analysis - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Analyzing drawdowns of 4D Molecular Therapeutics Inc. with statistical toolsHigh Conviction Screener with Trend Matching - Newser

Jul 28, 2025

4 D Molecular Therapeutics Inc Stock (FDMT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$77.32
price down icon 0.46%
$36.72
price down icon 1.08%
$108.64
price down icon 2.13%
$27.81
price down icon 2.38%
$113.20
price up icon 1.47%
biotechnology ONC
$295.02
price down icon 1.14%
Cap:     |  Volume (24h):